Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Andrew D. Campbell, MD
Researcher Director
Comprehensive Sickle Cell Disease Program
Children's National Health System
111 Michigan Avenue, NW
Washington, DC, United States
Dr. Campbell’s distinguished training and career path began at Morehouse College. He continued medical school at Case Western Reserve University and completed post graduate training at Massachusetts General Hospital (Harvard) and Lurie Children’s Hospital (Northwestern University). Prior to joining Children’s National, he was Director of the Comprehensive Sickle Cell Center at the University of Michigan, a position he held since 2005. His research interests span several topics in sickle cell disease including pulmonary complications, fetal hemoglobin switching in transgenic sickle cell mice, phenotype/genotype relationships, and renal complications.
Areas of Interest:
Pulmonary Hypertension in sickle cell disease
Phenotype/genotype Studies within twin and siblings with sickle cell disease
Morbidity and mortality in transitioning sickle cell patients
Fetal hemoglobin switching within sickle cell trangenic mice
Representative Publications:
Differences in the clinical and genotypic presentation of sickle cell disease around the world
An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes
mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease
Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease
Single-session biofeedback-assisted relaxation training in children with sickle cell disease
+myBinderRelated Content
-
Steven Hardy, PhDSteven Hardy, Ph.D. is the Director of P...
-
Disability evaluation under social security (hematological disorders – childhood)A. What hematological disorders do we ev...
-
CMO Speaks: Making ED Care Better for SCD – Progress in 2023Welcome to CMO Speaks, a blog featuring ...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
2023 NHLBI Annual Sickle Cell Disease Research MeetingSave the Date for the NHLBI Annual Sickl...
-
UC Davis Health, Department of PediatricsThe Section of Pediatric Hematology/Onco...
-
Simone C. Eastman Uwan, MDDr. Simone Eastman Uwan was born in Guya...
